Trial Profile
A Study to Evaluate the Pharmacokinetic and Pharmacodynamic of Ricolinostat and ACY-241 in Patients With Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Apr 2016
Price :
$35
*
At a glance
- Drugs Citarinostat (Primary) ; Ricolinostat (Primary)
- Indications Multiple myeloma
- Focus Biomarker; Pharmacodynamics; Pharmacokinetics
- 20 Apr 2016 Results presented at the 107th Annual Meeting of the American Association for Cancer Research
- 20 Apr 2016 New trial record